DecImmune Therapeutics Garners $2,250,000 Series A Financing Round
- Feed Type
- Link
http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=74e35046-0462-4c73-869a-60e61886cd3d&Preview=1 - Date
1/17/2013 - Company Name
DecImmune Therapeutics - Mailing Address
800 Huntington Ave. Boston, MA 02115 - Company Description
The company operates as a drug development company focused on inflammation. - Website
http://www.decimmune.com - Transaction Type
Venture Equity - Transaction Amount
$2,250,000 - Transaction Round
Series A - Proceeds Purposes
The funding announced today will support preclinical development of DecImmune’s therapeutic program targeting heart failure as an adjunct to current standards of care. Heart attack remains the leading cause of death in the United States, responsible for 1.2 million deaths per year. - M&A Terms
- Venture Investor
Broadview Ventures - Venture Investor
Astellas Venture Capital - Venture Investor
HealthCare Ventures
